Search results
Anti-IL-1β mAb
- Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
ir.avalotx.com › profile
People also ask
How do I contact Avalo Therapeutics (avtx)?
When will Avalo develop avtx-009?
When will Avalo's avtx-009 private placement close?
Who is Avalo Therapeutics?
Mar 27, 2024 · WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as...
Mar 29, 2024 · AVTX-009: Anti-IL-1β monoclonal antibody (mAb) targeting inflammatory diseases. Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa and expects topline data from its planned Phase 2 trial in hidradenitis suppurativa in 2026.
Mar 27, 2024 · WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as...
May 13, 2024 · Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com .
Mar 27, 2024 · Avalo Therapeutics (AVTX) experiences a surge in stock value after acquiring AVTX-009 and securing $185M in financing for its development in inflammatory...
Mar 27, 2024 · Avalo Therapeutics, Inc. acquires Phase 2-ready anti-IL-1β mAb AVTX-009 through the acquisition of AlmataBio, Inc. They executed a private placement financing of up to $185 million, with an initial upfront investment of $115.6 million, extending cash runway into 2027.